Friday, March 19, 2021 8:37:12 PM
Plus, we know Rememdesivir has been shown to have the potential to have hepatotoxicity since the current dose is close to the safe theraputic index...a ratio that compares the blood concentration at which a drug becomes toxic and the concentration at which the drug is effective.
The hepatotoxicity was first described in the Ebola studies and is now being reported in Covid 19 patients being treated with Remdesivir.
Below are several recent reports of Covid19 patients suffering liver damage due to Remdesivir.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386240/
"Our observation supports previous findings obtained in healthy volunteers (Gilead Sciences, data on file) and COVID-19 patients treated with RDV [4, 5], suggesting this antiviral may cause hepatocellular injury."
In addition Remdesivir has many drug interactions which can limit treatment of other life threatening conditions:
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa883/5864408
https://www.uptodate.com/contents/image/print?imageKey=EM%2F73326&topicKey=RHEUM%2F1666&source=see_link
Your contention that Brilacidin may have "known Serious Adverse Events" pales to the risk of Remdesivir. If a patients on Brilacidins blood pressure increases it is easily treatable and serious elevations of blood pressure were not demonstrated at the Brilacidin.6mg/kg dose. The tingling sensation has not been shown to be associated with neurologic or other long term complications.
The real question is would you rather have a drug with the potential to have profound effect against the Covid19 or a drug we know has little effect.
I will stand by my post.
My bet is after Brilacidins Phase2 trial there will be many requests across the country for compassionate use of Brilacidin for Covid 19 for the reasons I have outlined.
GLTA Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM